



ATTORNEY'S DOCKET NUMBER: 2004768-0018

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Michot <i>et al.</i>	Examiner:	Martin, A.
Serial No.:	10/789,453	Art Unit:	1745
Filing Date:	February 27, 2004		
Title:	Perfluorinated Amide Salts and Their Uses as Ionic Conducting Materials		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

**TRANSMITTAL LETTER**

Enclosed are the following documents:


1. Statement under 37 C.F.R. §§ 1.56, 1.97, and 1.98 (6 pages);
2. Form PTO-1449 (3 pages); and
3. Return Postcard.

Respectfully submitted,

  
Charles E. Lyon, D. Phil.  
Registration No. 56,630

Choate, Hall & Stewart, LLP  
Two International Place  
Boston, MA 02110  
t (617) 248-5000  
f (617) 248-4000

Dated: January 3, 2007

<b>Certificate of Mailing</b>	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
January 3, 2007	
Date	Signature
Nicole A. Dozier	
Typed or Printed Name of person signing certificate	



ATTORNEY DOCKET NO.: 2004768-0018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Michot <i>et al.</i>	Examiner:	Martin, A.
Serial No.:	10/789,453	Art Unit:	1745
Filing Date:	February 27, 2004		
Title:	Perfluorinated Amide Salts and Their Uses as Ionic Conducting Materials		

CERTIFICATE OF MAILING

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 3, 2007

Date

Signature

Nicole A. Dozier

Typed or Printed Name of person signing certificate

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

☒ An *original* Information Disclosure Statement; or

☐ A *supplemental* Information Disclosure Statement.

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
  - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
  - ☒ Before the mailing of a first Office action on the merits; or
  - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- ☐ Certifies that *either*:
    - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
    - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making

reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; or

☐ Includes herewith the fee set forth in § 1.17(p),

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☐ A copy of each cited reference not indicated with an asterisk is included, except for U.S. patents and published U.S. patent applications for which the submission requirements has been waived by the PTO in the Official Gazette Notice of August 5, 2003, for applications filed after June 30, 2003;
- ☐ A copy of each of the references cited on the attached form PTO-1449 (modified) is enclosed, except for U.S. patents and published U.S. patent applications for which the submission requirement has been waived by the PTO in the Official Gazette Notice of August 5, 2003, for applications filed after June 30, 2003;
- ☒ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status
09/125,797	December 3, 1998	Granted

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Includes one or more translations of a non-English citation; or
- ☐ Does contain non-English language citations

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC § 102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).


Respectfully submitted,

Dated: January 3, 2007

  
\_\_\_\_\_  
Charles E. Lyon, D. Phil.  
Registration No. 56,630

CHOATE, HALL & STEWART, LLP  
Two International Place  
Boston, Massachusetts 02110  
(617) 248-5000  
(617) 248-4000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

 Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/789,453
				Filing Date	February 27, 2004
				First Named Inventor	Michot <i>et al.</i>
				Art Unit	1745
Examiner Name	Martin, A				
Attorney Docket Number	2004768-0018				
Sheet	1	Of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-3,793,079	February 19, 1974	Brown <i>et al.</i>	
		US-4,851,307	July 25, 1989	Armand <i>et al.</i>	
		US-5,072,040	December 10, 1991	Armand	
		US-5,273,840	December 28, 1993	Dominey	
		US-5,446,134	August 29, 1995	Armand <i>et al.</i>	
		US-5,502,251	March 26, 1996	Pohmer <i>et al.</i>	
		US-5,514,493	May 7, 1996	Waddell <i>et al.</i>	
		US-5,609,990	March 11, 1997	Ha <i>et al.</i>	
		US-5,654,112	August 5, 1997	Itou <i>et al.</i>	
		US-5,691,081	November 25, 1997	Krause <i>et al.</i>	
		US-5,817,376	October 6, 1998	Everaerts <i>et al.</i>	
		US-5,874,616	February 23, 1999	Howells <i>et al.</i>	
		US-5,962,546	October 5, 1999	Everaerts <i>et al.</i>	
		US-6,063,522	May 16, 2000	Hamrock <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		*EP-0 571 832	May 13, 1993	Bayer AG		
		*EP-0 731 518	September 11, 1996	Minnesota Mining and Manufacturing Company		
		*WO-95/26056	September 28, 1995	Centre National de la Recherche Scientifique		
		*WO-96/24928	August 15, 1996	Minnesota Mining and Manufacturing Company		
		*WO-96/24929	August 15, 1996	Minnesota Mining and Manufacturing Company		
		*WO-97/23448	July 3, 1997	Minnesota Mining and Manufacturing Company		
		*WO-97/35929	October 2, 1997	Minnesota Mining and Manufacturing Company		
		*WO-97/35930	October 2, 1997	Minnesota Mining and Manufacturing Company		
		*WO-98/50349	November 12, 1998	Minnesota Mining and		



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/789,453	
			Filing Date	February 27, 2004	
			First Named Inventor	Michot <i>et al.</i>	
			Art Unit	1745	
			Examiner Name	Martin, A	
Sheet	3	Of	3	Attorney Docket Number	2004768-0018

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		*Banks et al., <i>Journal of Fluorine Chemistry</i> , <b>46</b> : 297-305, 1990.	
		*Lis et al., "Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds", <i>J. Med. Chem.</i> , <b>30</b> : 696-704, 1987.	
		*Potrov et al "Synthesis of Poly Fluoro-2-alleanesulfonyl-3,3-dialkyloxaziridinos" <i>Journal of Fluorine Chemistry</i> , <b>68</b> : 277-86, 1994.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 2313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*